The NM_005629.4:c.1601T>C variant in SLC6A8 is a missense variant predicted to cause the substitution of an isoleucine by a threonine at amino acid position 534 (p.Ile534Thr). To our knowledge, this variant has not been reported in the literature and no functional studies are available. In gnomAD v4.1.0., the highest population minor allele frequency (MAF) is 0.00001229 (11/894936 alleles, 6 hemizygotes) in the European (Non-Finnish) population. While this MAF is below the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.00002), PM2_Supporting cannot be applied due to the presence of hemizygotes. Overall, there are 7 hemizygotes in gnomAD v4.1.0 (6 in the European non-Finnish population and one in the remaining population) (BS2). The computational predictor REVEL gives a score of 0.474, which is less than the ClinGen CCDS VCEP’s threshold for PP3 (>0.75) but greater than the ClinGen CCDS VCEP’s threshold for BP4 (<0.2), such that neither of these criteria are met. There is a ClinVar entry for this variant (Variation ID: 212211). Due to the presence of 7 hemizygotes in gnomAD v4.1.0, the consensus of the CCDS VCEP is to classify this variant as likely benign for creatine transporter deficiency, a severe, pediatric onset neurodevelopmental disorder. SLC6A8-specific criteria applied, as specified by the ClinGen CCDS VCEP (Specifications Version 1.1.0): BS2 (Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on March 13, 2025)